SCHEMBL4809440

SCHEMBL4809440

O=C(CN1CCN(Cc2ccc([N+](=O)[O-])cc2)CC1)NCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.68
▸ CA2 P00918 1/20 0.68
▸ CA7 P43166 1/20 0.68
▸ CA9 Q16790 1/20 0.68
▸ L3MBTL1 Q9Y468 2/20 0.64
▸ ALDH1A1 P00352 3/20 0.63
▸ KDM4E B2RXH2 1/20 0.62
▸ ACHE P22303 3/20 0.61
▸ BCHE P06276 2/20 0.61
▸ BACE1 P56817 2/20 0.61
▸ SIGMAR1 Q99720 2/20 0.60
▸ HTR1A P08908 1/20 0.58
▸ HTR7 P34969 1/20 0.58
▸ FAAH O00519 1/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ USP2 O75604 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4818022 0.87 CA1 (0.76) CA1CA2CA7CA9ALDH1A1
SCHEMBL3838144 0.85 CA1 (0.55) CA1CA2CA7CA9ALDH1A1
SCHEMBL29078385 0.85 L3MBTL1 (0.67) CA1CA2CA7CA9L3MBTL1
SCHEMBL5626457 0.83 ALDH1A1 (0.74) L3MBTL1ALDH1A1KDM4EACHEBCHE
SCHEMBL4818357 0.83 CA1 (0.74) CA1CA2CA7CA9ALDH1A1
SCHEMBL3844592 0.82 HTT (0.79) CA1CA2CA7CA9ALDH1A1
SCHEMBL9610816 0.81 KDM4E (0.65) L3MBTL1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL8034304 0.81 KDM4E (0.65) L3MBTL1ALDH1A1KDM4ESMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL4474974 0.79 ALDH1A1 (0.70) L3MBTL1ALDH1A1KDM4ESIGMAR1SMN1; SMN2
SCHEMBL29078365 0.79 CYP2C19 (0.61) L3MBTL1ALDH1A1KDM4ESIGMAR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332495-B2 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent NHWA PHARMA. CORPORATION (CN) 2008-02-19 — — US claimed
US-20060148811-A1 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2006-07-06 — — US claimed
US-7332495-B2 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent NHWA PHARMA. CORPORATION (CN) 2008-02-19 — — US disclosed
US-20060148811-A1 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2006-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148811-A1 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent AAK1, KCNJ1, KHK CA1 3427/4885CA2 1495/4885CA7 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback